Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP notes despite the incredible clinical and commercial success of JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.
JMP證券開始對Summit Therapeutics Inc. (納斯達克:SMMT) 進行覆蓋，指出該公司最初專注於傳染病。後來，於2022年，該公司轉向腫瘤學，並從康方生物處特許許可了ivonescimab (PD-1 X VEGF雙特異性)，前期支付5千萬美元，潛在里程碑達到50億美元。
The analyst says, "We believe Summit shares represent a unique investment opportunity."
分析師表示：「我們認爲Summit股票代表了一個獨特的投資機會。」
Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
JMP指出，儘管默沙東 (Merck) 和大日本製藥合作的肺癌候選藥物在晚期研究中達到主要目標
JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc's (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co's (NYSE:BMY) Opdivo (nivolumab), ivonescimab seems as if a formidable opponent has appeared offering higher response rates and a longer median progression-free survival.
JMP指出，儘管默克 (NYSE:MRK) 的Keytruda (pembrolizumab) 和必治客 (Bristol Myers Squibb & Co) (NYSE:BMY) 的Opdivo (nivolumab) 取得了令人難以置信的臨床和商業成功，但ivonescimab似乎出現了一位強大的對手，提供更高的應答率和更長的中位無進展生存期。
In September, Summit Therapeutics released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China.
今年9月，Summit Therapeutics發佈了中國進行的ivonescimab第3期HARMONi-2試驗的初步分析數據。
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial's primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio (HR) of 0.51.
Ivonescimab單藥療法在試驗的主要終點，無進展生存期，相對於單藥療法帕博利珠單抗，表現出了統計學顯著改善，取得了0.51的風險比（HR）。
JMP initiated Summit Therapeutics with a Market Outperform rating and a price target of $32.
JMP開始評級Summit Therapeutics爲市場表現優異，並設定目標價格爲32美元。
The analyst also notes that while the overall survival data are still in progress, Ivonescimab has a strong chance of showing an overall survival advantage over pembrolizumab in first-line non-small cell lung cancer in a future data update.
該分析師還指出，儘管整體生存數據仍在進行中，但在未來的數據更新中，Ivonescimab有很大機會在一線非小細胞肺癌中展示出對帕博利珠單抗的整體生存優勢。
The analyst notes that with numerous global Phase 3 studies in progress and strong head-to-head data for monotherapy, Summit is positioned to potentially commercialize its treatment in the more targeted EGFRm and first-line NSCLC patient groups.
分析師指出，隨着全球多個第3期研究的進行以及針對單藥療效的強大頭對頭數據，summit therapeutics有望在更具針對性的EGFRm和一線NSCLC患者群體中潛在地實現治療商業化。
If successful, this could lead to an estimated $17.9 billion in peak global revenue upon potential entry into the first-line NSCLC market by 2034.
若取得成功，這將導致summit在2034年進入一線NSCLC市場後，全球營業收入達到預計的179億美元峯值。
Price Action: SMMT stock is up 5.33% at $20.00 at last check Monday.
價格走勢：週一最後一次檢查時，SMMt股價上漲5.33%，報20.00美元。
Photo via Shutterstock
圖片來自shutterstock。
- AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
- 阿斯利康發佈與中國公司合作的口服減肥藥的早期數據
譯文內容由第三人軟體翻譯。
